Trial Profile
A Phase 1, Parallel-group, Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ranolazine ER in Subjects With Severe Renal Impairment as Compared to Healthy Subjects With Normal Renal Function
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Atrial fibrillation; Heart failure; Myocardial ischaemia; Paroxysmal atrial fibrillation; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 07 Sep 2012 New trial record
- 01 Aug 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.